Loading
Latigo Biotherapeutics, Inc. Stock: price and insider trades · United States
1 insider bought €2.2M of shares over the last 90 days, the latest by Foresite Capital Management V, LLC, filed 10 Aug 2026.
Insider Decl.
34
Thresholds
n/a
Buy Volume
€2M
1 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleForesite Capital Management V, LLC1 buy
Since the insiders bought
- -11.8%Entry US$18.52 · Close 21 Oct 2026 US$16.34
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Latigo Biotherapeutics, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$52.25.
Financial data
as of FY 2025FY ended December 2025 · cache
US$15.25
Analyst consensus
4 analystsStrong buy
US$36.00Target US$52.25(+243%)US$73.00
Income statement
EBITDA-US$110.1M
Net income-US$109.2M0.0% margin
Balance sheet & cash
Market capUS$1B
Total debtUS$690k
Free Cash Flow-US$97.7M
Debt / Equity250%
Profitability & ownership
% insiders5.0%
% institutions80.4%
Last declaration on 12 August 2026
Declarations34 total
4,975,543 sharesCommon StockSEC:0001231919-26-000869:0
2,350,419 sharesCommon StockSEC:0001231919-26-000869:1
494,800 sharesCommon StockSEC:0001193125-26-345826:0
177,978 sharesCommon StockSEC:0001193125-26-345826:1
938,979 sharesCommon StockSEC:0001104659-26-093633:0
3,547,842 sharesCommon StockSEC:0001104659-26-093633:1
1,027,635 sharesCommon StockSEC:0001104659-26-093633:2
3,464,072 sharesCommon StockSEC:0001104659-26-093633:3
1,484,401 sharesCommon StockSEC:0001104659-26-093633:4
165,519 sharesCommon StockSEC:0001104659-26-093633:5
2,066,857 sharesCommon StockSEC:0001104659-26-093633:6
3,117,664 shares0Common StockSEC:0001104659-26-093580:0
445,320 shares0Common StockSEC:0001104659-26-093580:1
742,201 shares0Common StockSEC:0001104659-26-093580:3
3,117,664 shares0Common StockSEC:0001104659-26-093580:6
296,880 shares0Common StockSEC:0001104659-26-093580:7
938,979 sharesCommon StockSEC:0001184592-26-000005:0
195,776 sharesCommon StockSEC:0001581754-26-000006:5
3,117,664 sharesCommon StockSEC:0001581754-26-000006:6
1,125,823 shares0Common StockSEC:0001104659-26-093580:2
195,776 sharesCommon StockSEC:0001104659-26-093580:5
3,547,842 sharesCommon StockSEC:0001184592-26-000005:1
1,027,635 sharesCommon StockSEC:0001184592-26-000005:2
3,464,072 sharesCommon StockSEC:0001184592-26-000005:3
1,484,401 sharesCommon StockSEC:0001184592-26-000005:4
25 of 34 declarations
About Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. has a record of 33 filings, all published between August 10 and August 12, 2026, with a single open-market trade: a purchase of EUR 2,180,556, filed by Foresite Capital Management V, LLC, 10% Owner, for August 10, 2026. The rest, 32 filings, is of another kind, and no sale is recorded.
Foresite Capital Management V, LLC files 8 of them. Westlake BioPartners Fund I, L.P., also 10% Owner, files 7, as do Beth C. Seidenberg and James B. Tananbaum, both Director. 5AM Ventures VI, L.P., 10% Owner, files 2. Six filers appear in the record.
Read moreShow less
Filings appear on the day of the trade at the median. The 33 filings alone make up 2026 and the last twelve months. This US health company has a market capitalisation of USD 1.01 billion, with 5% of the shares held by insiders. These 33 filings come from 6 insiders. By kind, the record holds 32 other filings and 1 purchase.
